[{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Novaliq","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"15","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"Peroxisome proliferator-activated receptor delta","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"14-C SJP-0008","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Quotient Sciences"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SJP-0132","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD"}]

Find Clinical Drug Pipeline Developments & Deals by SENJU PHARMACEUTICAL CO LTD

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : SJP-0132 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : SJP-0132

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : SENJU PHARMACEUTICAL CO LTD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          July 23, 2024

                          Lead Product(s) : Fonadelpar

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Recipient : Eyenovia

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear e...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          June 13, 2023

                          Lead Product(s) : Perfluorohexyloctane

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Recipient : Novaliq

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : 14-C SJP-0008 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          April 11, 2022

                          Lead Product(s) : 14-C SJP-0008

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Quotient Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.

                          Product Name : Ailamide

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 16, 2020

                          Lead Product(s) : Brimonidine Tartrate,Brinzolamide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank